Insider Selling: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Sells 32,922 Shares of Stock

Posted by Doug Wharley on Mar 31st, 2025

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 32,922 shares of the business’s stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $13.01, for a total transaction of $428,315.22. Following the sale, the insider now directly owns 3,240,630 shares of the company’s stock, valued at approximately $42,160,596.30. The trade was a 1.01 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.62, for a total value of $2,724.00.
On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.75, for a total transaction of $502,370.00.
On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.95, for a total transaction of $599,668.65.
On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.03, for a total transaction of $25,899.38.
On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.27, for a total transaction of $216,090.61.
On Wednesday, January 29th, Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.12, for a total transaction of $164,836.88.

Abrdn Life Sciences Investors Stock Down 2.9 %

Shares of HQL traded down $0.37 during mid-day trading on Monday, hitting $12.51. 153,854 shares of the company were exchanged, compared to its average volume of 129,266. The company has a 50 day moving average of $13.58 and a 200-day moving average of $14.11. Abrdn Life Sciences Investors has a 1-year low of $12.37 and a 1-year high of $15.90.

Abrdn Life Sciences Investors Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, February 21st will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 15.03%. The ex-dividend date of this dividend is Friday, February 21st.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BankPlus Trust Department purchased a new position in shares of Abrdn Life Sciences Investors during the fourth quarter worth about $28,000. Steward Partners Investment Advisory LLC raised its holdings in Abrdn Life Sciences Investors by 379.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company’s stock worth $64,000 after purchasing an additional 3,847 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in Abrdn Life Sciences Investors during the 4th quarter valued at about $154,000. Kingswood Wealth Advisors LLC acquired a new stake in Abrdn Life Sciences Investors during the 4th quarter valued at $160,000. Finally, Sanctuary Advisors LLC raised its holdings in Abrdn Life Sciences Investors by 11.4% in the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock valued at $183,000 after acquiring an additional 1,355 shares during the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.